BBNX logo

BBNXBeta Bionics Inc.

$13.72
$0.67
(4.66%)
Today
Closed $13.72
$0.05
(0.36%)
After Hours
Updated: 07:47 PM EDT
EarningsJul 21
Mkt Cap$641.24M
Vol712,896.00
News
all
press releases
Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth
Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth PR Newswire SAN DIEGO, June 5, 2026 SAN...
PR Newswire
News Placeholder
More News
News Placeholder
Beta Bionics Investors Suffer Significant Losses After Company Reports Slower New Patient Start Growth; Contact Johnson Fistel
Johnson Fistel, PLLP is investigating whether Beta Bionics, Inc. (NASDAQ: BBNX) or certain of its executive officers violated federal securities laws. The investigation focuses on investors losses and whether they may be recovered under federal securities laws.What if I purchased Beta Bionics...
Business Wire
News Placeholder
BBNX Shareholder Alert: Robbins LLP Reminds Beta Bionics, Inc. Stockholders that it is Investigating the Company's Officers and Directors to Determine if They Violated Securities Laws and Breached Fiduciary Duties to Shareholders
BBNX Shareholder Alert: Robbins LLP Reminds Beta Bionics, Inc. Stockholders that it is Investigating the Company's Officers and Directors to Determine if They Violated Securities Laws and Breached Fiduciary Duties to Shareholders BBNX Shareholder Alert: Robbins LLP Reminds Beta Bionics, Inc...
PR Newswire
News Placeholder
Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders
Shareholder Rights law firm Robbins LLP is investigating Beta Bionics, Inc. (NASDAQ: BBNX) to determine whether certain Beta Bionics officers and directors violated securities laws and breached fiduciary duties to shareholders. Beta Bionics is a commercial-stage medical device company, engages in...
Business Wire
News Placeholder
Beta Bionics, Inc. (NASDAQ:BBNX) Given Average Rating of "Moderate Buy" by Analysts
Shares of Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) have been given an average rating of "Moderate Buy" by the twelve brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold re...
MarketBeat
News Placeholder
Beta Bionics (NASDAQ:BBNX) Price Target Cut to $24.00 by Analysts at Leerink Partners
Leerink Partners decreased their price target on Beta Bionics from $25.00 to $24.00 and set an "outperform" rating on the stock in a research note on Wednesday...
MarketBeat
News Placeholder
Beta Bionics (NASDAQ:BBNX) Shares Gap Up on Strong Earnings
Beta Bionics (NASDAQ:BBNX) Shares Gap Up on Earnings Beat...
MarketBeat
News Placeholder
Beta Bionics (NASDAQ:BBNX) Given New $20.00 Price Target at Stifel Nicolaus
Stifel Nicolaus reduced their target price on Beta Bionics from $22.00 to $20.00 and set a "buy" rating on the stock in a research note on Wednesday...
MarketBeat
News Placeholder
Beta Bionics Q1 Earnings Call Highlights
Beta Bionics (NASDAQ:BBNX) reported first-quarter 2026 net sales of $27.6 million, up 57% year-over-year, as management cited growth in new patient starts, a rising base of recurring pharmacy users, and continued expansion of pharmacy channel access for its iLet insulin delivery system. Quarterly r...
MarketBeat
News Placeholder
Beta Bionics BBNX Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
<
1
2
...
>

Advertisement|Remove ads.